Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Publication year range
1.
Clín. investig. arterioscler. (Ed. impr.) ; 36(1): 35-37, Ene. -Feb. 2024. ilus, tab
Article in English | IBECS | ID: ibc-230452

ABSTRACT

“The lower, the better” is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas. (AU)


«Cuanto más bajo, mejor» es el enfoque recomendado en el tratamiento del colesterol LDL alto. Lamentablemente esto no siempre se logra como en el caso de una mujer de 69 años remitida a nuestro Instituto por su perfil lipídico (colesterol LDL 412 mg/dL), xantelasma bilateral y xantomas cutáneos. Con terapias hipolipemiantes maximizadas y personalizadas (rosuvastatina, ezetimiba, iPCSK9 y aféresis de lipoproteínas), después de solo seis meses, la paciente mostró una regresión impresionante en sus xantomas cutáneos. (AU)


Subject(s)
Humans , Female , Aged , Hyperlipoproteinemia Type II/drug therapy , Hyperlipoproteinemia Type II/therapy , Xanthomatosis/drug therapy , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/therapeutic use
2.
Clin Investig Arterioscler ; 36(1): 35-37, 2024.
Article in English, Spanish | MEDLINE | ID: mdl-38016879

ABSTRACT

"The lower, the better" is the recommended approach in the management of high LDL cholesterol. Unfortunately, this does not always achieve as in the case of a 69-year-old woman referred to our Institute for her lipid profile (LDL cholesterol 412mg/dl), bilateral xanthelasma and cutaneous xanthomas. With a maximized and personalized lipid-lowering therapies (rosuvastatin, ezetimibe, PCSK9i and lipoprotein apheresis), after only six months, the patient showed an impressive regression in her cutaneous xanthomas.


Subject(s)
Anticholesteremic Agents , Hypercholesterolemia , Hyperlipoproteinemia Type II , Xanthomatosis , Humans , Female , Aged , Cholesterol, LDL , Hyperlipoproteinemia Type II/drug therapy , Ezetimibe/therapeutic use , Xanthomatosis/etiology , Anticholesteremic Agents/pharmacology , Anticholesteremic Agents/therapeutic use
3.
Surg. cosmet. dermatol. (Impr.) ; 12(4 S2): 270-274, fev.-nov. 2020.
Article in Portuguese | LILACS-Express | LILACS | ID: biblio-1368223

ABSTRACT

Este estudo demonstrou o excelente resultado do tratamento de xantelasma palpebrarum recidivado com laser ablativo. A paciente foi submetida a uma única sessão de laser Érbio: ítrio-alumínio-granada (Fotona®) 2940nm, e registros fotográficos foram realizados com Vectra® H2 2019 antes e após o procedimento. O tratamento com laser mostrou resultados clínicos satisfatórios, boa tolerabilidade álgica, recuperação precoce, quando comparado a procedimentos cirúrgicos, e menor tempo de afastamento das atividades laborais


Case study of exceptional response to treatment of recurrent xanthelasma palpebrarum with an ablative laser. The patient underwent a single session of laser Erbium: Yttrium-aluminum-garnet (Fotona®) 2940 nm, and we performed photographic records with Vectra® H2 2019 before and after the procedure. Satisfactory clinical results were reported, with good pain tolerability and early recovery compared to surgical procedures and, consequently, less time away from work activities.

4.
Curr Health Sci J ; 42(4): 417-421, 2016.
Article in English | MEDLINE | ID: mdl-30581598

ABSTRACT

Histiocytic disorders are a group of rare diseases with systemic involvement and with multiple clinical manifestations. We present the case of a 51 years old patient investigated for dyspnea with orthopnea, dry cough, asthenia, muscular weakness and ataxia. The association of previous symptoms with skin lesions, diabetes insipidus, partial hypophyseal insufficiency and pericarditis induced many diagnostic debates. The diagnosis is Histiocytosis X must be sustained by tissue biopsy with immunohistochemical assay or genetic testing. The particularity of our patient is the presence of pericarditis, rarely associated with histiocytosis. Collaboration between medical specialties is mandatory in order to treat this disorder.

SELECTION OF CITATIONS
SEARCH DETAIL
...